drug_type
RELEVANT_DRUG
intervention_type
Biological (Vaccine)
drug_description
A live-attenuated influenza B delNS viral vector vaccine encoding HPV16 E6/E7, administered intratumorally then intramuscularly to induce robust HPV16 E6/E7–specific CD8+ and CD4+ T-cell responses via heightened type I interferon signaling and dendritic cell activation, promoting MHC I–restricted tumor cell killing.
nci_thesaurus_concept_id
C200854
nci_thesaurus_definition
A cancer vaccine comprised of a modified influenza viral vector that lacks the C-terminal part of the non-structural gene NS1 (delNS) encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration, modified influenza virus expressing HPV16 E6/E7 FluBHPVE6E7 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. HPV16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.
drug_mesh_term
Neoplasm Vaccines
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Intratumoral, Intramuscular
drug_mechanism_of_action
Live-attenuated influenza B delNS viral vector encoding HPV16 E6/E7 delivered intratumorally then intramuscularly to drive strong innate sensing and type I interferon, activate dendritic cells and antigen presentation, and prime HPV16 E6/E7–specific CD8+ and CD4+ T-cell responses, resulting in MHC I–restricted cytotoxic killing of HPV16-positive tumor cells.
drug_name
FluBHPVE6E7
nct_id_drug_ref
NCT06589609